StockWatch
·
Q2 FY-2027 RESULTS · HSCL

Himadri Q2 FY27: Consolidated PAT +31% YoY to ₹231 Cr, Margins Slip on 58% Revenue Jump

PAT +31.33% YoY · revenue +57.93% · margins compressing · beat vs street

Q2 FY27 resultsHSCLHimadri Speciality Chemical Ltd16 Oct 2026 · 3 min read
Revenue

₹1,691.43 Cr

+57.93% YoY

PAT (consolidated)

₹231.32 Cr

+31.33% YoY

Net margin

13.35%

-2.6pp YoY

EPS

₹4.6

Himadri Speciality Chemical's consolidated PAT rose 31.3% YoY to ₹231.32 Cr (EPS ₹4.60 vs ₹3.58) on revenue of ₹1,691.43 Cr, up 57.9% YoY and 18.1% QoQ from ₹1,431.88 Cr in Q1 FY27. Against our pre-result preview (consolidated revenue ₹1,350–1,400 Cr, PAT ₹210–230 Cr), the top line beat by roughly 21% above the high end while PAT landed just above the top of the range — a clear revenue beat that only partially converted to the bottom line.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,691.43 Cr+18.1%+57.9%
Expenses₹1,425.88 Cr+20.1%+63.8%
PAT₹231.32 Cr+1.27%+31.33%
Net margin13.35%-2pp-2.6pp
EPS₹4.6+1.1%+28.5%

The gap is a margin story: operating margin (per the filing's own ratio, PBT + depreciation + finance costs − other income, over revenue) came in at 17.93%, down from 22.21% in the year-ago quarter and 21.87% last quarter; net profit margin fell to 13.68% from 16.45% YoY and 15.95% QoQ. In absolute terms that operating-profit measure works out to roughly ₹303 Cr — squarely inside the preview's ₹300–310 Cr EBITDA-band despite revenue running ~21% ahead of what the preview assumed, meaning the incremental revenue carried materially lower margin than the base business. Finance costs held flat YoY (₹27.72 Cr) and the tax rate was unremarkable (24.7% of PBT), so the squeeze sits upstream, in cost of materials and other expenses, consistent with a richer mix from newly consolidated, lower-margin units.

₹
617.61668.34719.08769.81820.54660.707-1308-0508-2809-2310-16Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹660.7, up 1.2% over the past month of trading.

₹ Cr
086.36172.72259.08179.36Q1 FY26rev ₹1,118 Cr176.14Q2 FY26rev ₹1,071 Cr192.04Q3 FY26rev ₹1,184 Cr207.53Q4 FY26rev ₹1,288 Cr228.43Q1 FY27rev ₹1,432 Cr231.32Q2 FY27rev ₹1,691 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
Management provided strong forward-looking guidance, expecting substantial growth driven by new energy materials and advanced products. The company anticipates revenue potential of INR3,000 Crores from LFP cathode expansion by FY28, INR250-300 Crores from anthraquinone/carbazole, INR500 Crores from Super Speciality Car

— This quarter: met

Standalone (parent-only) tells a milder version: revenue of ₹1,542.67 Cr grew 44.1% YoY and PAT of ₹239.77 Cr grew 28.3% YoY — both well short of the consolidated growth rates. The divergence traces to the "Others" segment (₹144.14 Cr this quarter, nil in the year-ago quarter), which reflects Himadri Integrated Minerals and Resources (consolidated from February 2026) and Ardent Impex Fzco, Dubai (from June 2026) — businesses with no footprint in the September-2025 base, so part of the headline consolidated growth is a consolidation effect rather than organic expansion. Street coverage remains thin, as flagged pre-result (effectively one analyst on record, Hold rating, targets split ₹480–720), so there is no independent quarterly consensus to check against beyond that FY27 full-year estimate (+34.8% revenue, +23.8% EPS, per Trendlyne) — this quarter's growth pace is broadly consistent with that trajectory. Management issued no press release alongside this filing (none available in our records), so there is no fresh management framing to reconcile against the numbers this quarter.

  • W1

    Anthraquinone Phase 1 ramp — not separately broken out in this filing's segments; confirm contribution in next quarter's disclosure or management commentary

  • W2

    Margin trajectory — OPM at 17.93% this quarter (vs 22.21% YoY); FY28 PAT target of ₹1,100 Cr implies margin recovery is needed alongside revenue growth

  • W3

    DBRL tyre-business demerger scheme — pending stock-exchange/regulatory sanction; watch for approval timeline and share entitlement ratio execution

Informational and educational content only. Not investment advice.